[go: up one dir, main page]

PE20090435A1 - Inhibidores de tetrahidropiranocromeno de gamma secretasa - Google Patents

Inhibidores de tetrahidropiranocromeno de gamma secretasa

Info

Publication number
PE20090435A1
PE20090435A1 PE2008001121A PE2008001121A PE20090435A1 PE 20090435 A1 PE20090435 A1 PE 20090435A1 PE 2008001121 A PE2008001121 A PE 2008001121A PE 2008001121 A PE2008001121 A PE 2008001121A PE 20090435 A1 PE20090435 A1 PE 20090435A1
Authority
PE
Peru
Prior art keywords
alkyl
alkylene
tetrahydropyranochromene
inhibitors
gamma secretase
Prior art date
Application number
PE2008001121A
Other languages
English (en)
Inventor
Thomas A Bara
Duane A Burnett
John W Clader
Martin S Domalski
Yan Jin
Hubert B Josien
Hongmei Li
Xian Liang
Dmitri Pissarnitski
Travalakulamgara K Sasikumar
Jesse K Wong
Ruo Xu
Zhiqiang Zhao
Paul E Mcnamara
Wen-Lian Wu
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20090435A1 publication Critical patent/PE20090435A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA (I), DONDE X ES N, CH2; R1 ES -ALQUILEN-SO2-ALQUILO(C1-C6), -ALQUILEN-SO2-HALOALQUILO(C1-C6), ALQUILEN-(1,1-DIOXIDO DE TETRAHIDROTIOFENO), ENTRE OTROS; R2 ES H, ALQUILO; Ar ES ARILO, HETEROARILO, ARILO SUSTITUIDO CON UNO O MAS L1A, ENTRE OTROS; L1A ES HALOGENO, ALQUILO, -CN, CF3, -O-(HALOALQUILO(C1-C6)), ENTRE OTROS; L1 ES HALOGENO, -CN, -CF3, -O-ALQUILO(C1-C6), -C(O)-O-ALQUILO(C1-C6), ALQUILEN-OH, ENTRE OTROS; n ES 0-3. SON COMPUESTOS PREFERIDOS: (a), (b), ENTRES OTROS. SE REFIERE TAMBIEN UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDRORES DE GAMMA-SECRETASA, UTILES EN EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS, ENFERMEDAD DE ALZHEIMER E INHIBIENDO EL DEPOSITO DE PROTEINA AMIELOIDE EN, SOBRE O ALREDEDOR DEL TEJIDO NEUROLOGICO
PE2008001121A 2007-07-05 2008-07-02 Inhibidores de tetrahidropiranocromeno de gamma secretasa PE20090435A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94803307P 2007-07-05 2007-07-05

Publications (1)

Publication Number Publication Date
PE20090435A1 true PE20090435A1 (es) 2009-04-18

Family

ID=39830164

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001121A PE20090435A1 (es) 2007-07-05 2008-07-02 Inhibidores de tetrahidropiranocromeno de gamma secretasa

Country Status (16)

Country Link
US (1) US8664411B2 (es)
EP (1) EP2435416B1 (es)
JP (1) JP5240871B2 (es)
KR (1) KR20100044197A (es)
CN (1) CN101754960A (es)
AR (1) AR067445A1 (es)
AU (1) AU2008275735B2 (es)
BR (1) BRPI0814256A8 (es)
CA (1) CA2691542A1 (es)
CL (1) CL2008001960A1 (es)
CO (1) CO6270309A2 (es)
EC (1) ECSP109845A (es)
PE (1) PE20090435A1 (es)
RU (1) RU2483061C2 (es)
TW (1) TW200908959A (es)
WO (1) WO2009008980A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102702044A (zh) 2006-01-20 2012-10-03 先灵公司 作为γ分泌酶抑制剂的碳环和杂环芳基砜化合物
CA2693216A1 (en) * 2007-07-17 2009-01-22 Schering Corporation Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
US8933116B2 (en) * 2011-04-04 2015-01-13 Merck Sharp & Dohme Corp. Gamma secretase inhibitors
US9226927B2 (en) * 2011-09-09 2016-01-05 Merck Sharp & Dohme Corp. Gamma secretase inhibitors
WO2014085211A2 (en) * 2012-11-29 2014-06-05 Merck Sharp & Dohme Corp. Spirocyclic sulfones as gamma secretase inhibitors
KR102209418B1 (ko) 2012-12-20 2021-01-29 얀센 파마슈티카 엔.브이. 감마 세크레타제 조절 인자로서의 신규 삼환 3,4-디하이드로-2H-피리도[1,2-α]피라진-1,6-디온 유도체
CN104936958B (zh) 2013-01-17 2019-07-26 詹森药业有限公司 作为γ分泌酶调节剂的新颖的经取代的吡啶并-哌嗪酮衍生物
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
CA3042877A1 (en) * 2016-11-09 2018-05-17 Bristol-Myers Squibb Company Tricyclic sulfones as ror gamma modulators
WO2018226992A1 (en) 2017-06-07 2018-12-13 Adrx, Inc. Tau aggregation inhibitors
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
US11453701B2 (en) 2017-08-18 2022-09-27 Adrx, Inc. Tau aggregation peptide inhibitors
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
CA3185040A1 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000050391A1 (en) 1999-02-26 2000-08-31 Merck & Co., Inc. Novel sulfonamide compounds and uses thereof
FR2827590B1 (fr) * 2001-07-18 2003-10-24 Atuser Transbordeur de liquides alimentaires usages
GB0108591D0 (en) * 2001-04-05 2001-05-23 Merck Sharp & Dohme Therapeutic agents
CN1304390C (zh) 2001-08-03 2007-03-14 先灵公司 新颖的γ—分泌酶抑制剂
RU2202370C1 (ru) * 2001-12-26 2003-04-20 Эпштейн Олег Ильич Нейропсихотропное лекарственное средство
GB0222833D0 (en) 2002-10-02 2002-11-06 Syngenta Ltd Chemical process
GB0223039D0 (en) * 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
NZ542797A (en) 2003-05-16 2007-12-21 Merck Sharp & Dohme Cyclohexyl sulfones comprising an additional fused ring cyclic sulfonamide group suitable for inhibition of gamma-secretase
GB0317491D0 (en) * 2003-07-25 2003-08-27 Novartis Ag Organic compounds
DE102005062098A1 (de) * 2005-12-22 2007-06-28 Merck Patent Gmbh Oxaphenanthren-Derivate
CN102702044A (zh) * 2006-01-20 2012-10-03 先灵公司 作为γ分泌酶抑制剂的碳环和杂环芳基砜化合物
TW200813054A (en) 2006-06-02 2008-03-16 Elan Pharm Inc Fused, tricyclic sulfonamide inhibitors of gamma secretase
CN102282145A (zh) 2008-11-13 2011-12-14 先灵公司 γ分泌酶调节剂

Also Published As

Publication number Publication date
JP5240871B2 (ja) 2013-07-17
BRPI0814256A8 (pt) 2016-02-10
AU2008275735A1 (en) 2009-01-15
ECSP109845A (es) 2010-02-26
BRPI0814256A2 (pt) 2015-02-03
RU2010103716A (ru) 2011-08-10
CN101754960A (zh) 2010-06-23
AR067445A1 (es) 2009-10-14
AU2008275735A2 (en) 2010-02-11
WO2009008980A3 (en) 2009-03-19
AU2008275735B2 (en) 2014-03-27
TW200908959A (en) 2009-03-01
KR20100044197A (ko) 2010-04-29
US8664411B2 (en) 2014-03-04
EP2435416B1 (en) 2016-03-30
US20110236400A1 (en) 2011-09-29
CO6270309A2 (es) 2011-04-20
EP2435416A2 (en) 2012-04-04
CL2008001960A1 (es) 2009-11-27
CA2691542A1 (en) 2009-01-15
RU2483061C2 (ru) 2013-05-27
WO2009008980A2 (en) 2009-01-15
JP2010532359A (ja) 2010-10-07

Similar Documents

Publication Publication Date Title
PE20090435A1 (es) Inhibidores de tetrahidropiranocromeno de gamma secretasa
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20161225A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
PE20211810A1 (es) Compuestos novedosos
PE20060150A1 (es) Antagonistas de cgrp seleccionados, composiciones farmaceuticas y procedimiento para su preparacion
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20081532A1 (es) Compuestos novedosos
PE20110063A1 (es) DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE20080730A1 (es) Derivados de fenilo como moduladores del receptor s1p
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20060241A1 (es) 2-quinolil-oxazoles sustituidos como inhibidores de pde4
PE20090772A1 (es) Derivados de bencimidazol
PE20080677A1 (es) Inhibidores de pirrolotriazina cinaza
PE20170947A1 (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20120505A1 (es) Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
PE20070136A1 (es) COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1
PE20050874A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
PE20080409A1 (es) Compuestos que modulan en el receptor cb2
AR060604A1 (es) Nuevos arilamino n- heteroarilos como inhibidores de mek
PE20081530A1 (es) Nuevos compuestos 617
PE20120790A1 (es) 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3

Legal Events

Date Code Title Description
FC Refusal